FDA Inspection 1169446 - Aurobindo Pharma Limited - May 10, 2022

FDA Inspection 1169446 for Aurobindo Pharma Limited on May 10, 2022. Classification: Voluntary Action Indicated (VAI).

One-time purchase from the GKS catalog. Lifetime access in your library. Single documents and full company profiles available. All sales final.

Record Summary

FDA Inspection 1169446 for Aurobindo Pharma Limited on May 10, 2022. Classification: Voluntary Action Indicated (VAI).

Violation Codes

21 CFR 211.100(a)

21 CFR 211.166(a)

21 CFR 211.188

21 CFR 211.192

21 CFR 211.63

21 CFR 211.68(b)

Get More Insights

Access our comprehensive regulatory intelligence platform to analyze patterns, track compliance trends, and stay ahead of regulatory changes.

1.5M+ regulatory data points

Real-time compliance monitoring

Interactive analytics dashboard

Looking for more records? Our platform provides access to thousands of similar regulatory documents with advanced search and filtering capabilities.

Record Information

Company

Aurobindo Pharma Limited

Inspection Date

May 10, 2022

Product Type

Drugs

Office

Center for Drug Evaluation and Research

ID: b9201ac7-5ec4-46dd-8aaf-7304c3c93094

View on Dashboard

Transform Regulatory Data into Actionable Intelligence

Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.

Try KeyPedia Today

Explore our real use cases and discover our features in depth.

Subscribe to our newsletter

Get the latest updates and insights delivered to your inbox